Biocon Seeks Partner to Sell Rival Drug to J&J’s Stelara

Biocon Ltd., India’s largest publicly traded biotechnology company, is in talks with U.S. drugmakers to co-develop and sell a psoriasis treatment that may rival Johnson & Johnson’s Stelara.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.